image

Authoritative Independent Monthly Share Selections Using Technical & Fundamental Analysis

Latest issue now available

SIGN UP NOW
Updates

Dechra Pharmaceuticals

April 2005

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • DPH
  • Price:
  • 205p
The shares burst through the £2 mark after Dechra revealed strong results for the six months ended 31 December. Underlying pretax profit increased 24% to £4.6m from a 12% jump in sales to £103m, while earnings rose 22% to 6.3p. Dechra's larger services division, a wholesale distributor of pharmaceuticals and pet products, grew revenues by a creditable 12%. This was thanks to both gains in its market share to 42.5% and also a buoyant animal healthcare market still clawing back business lost because of the BSE era. However, the key to significant share price growth is Dechra's smaller Pharmaceuticals division, which supplies own-branded and licensed branded veterinary products and grew sales ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Related Articles

Dechra Pharmaceuticals (November 2010)
Dechra Pharmaceuticals - US launch of Vetoryl to boost profits (February 2010)
Dechra Pharmaceuticals (November 2008)
Dechra Pharmaceuticals - US blockbuster potential for key drug (August 2008)
Dechra Pharmaceuticals - Impending US drug approval could herald profit surge (April 2007)
Dechra Pharmaceuticals - Gains approach £1 per share (November 2005)
Dechra Pharmaceuticals - Positive AGM (December 2004)
Dechra Pharmaceuticals - New animal drug could be blockbuster (October 2004)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X